Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Refractory Testicular Germ Cell Cancer
NCT01466231Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2011
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in Testicular Germ Cell Tumor (TGCT), sponsored by National Cancer Institute. Started Nov 2011; status: completed.
02
Drugs
everolimus
03
Conditions
Testicular Germ Cell Tumor (TGCT)
Beyond the preview
Go deeper on NCT01466231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01466231.